Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDe-2: Extension Study of Oral deucrictibant for Acute Treatment of Hereditary Angioedema Attacks
jRCT2061240060Phase 3Recruiting
- Sponsor
- Pharvaris
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Started Nov 2024; status: recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2061240060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240060.